Sema4 Holdings Corp.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jason Ryan
- Full Time Employees
- 1,200
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- North Tower Stamford CT United States of America 06902
- IPO Date
- Nov 4, 2020
- CIK
- 0001818331
- Website
- sema4.com
- Similar Companies
- Business
- Sema4 Holdings Corp. (SMFR), now operating as GeneDx Holdings Corp. (NASDAQ: WGS), provides genetic testing services focused on pediatric, rare disease, hereditary risk, and cancer diagnostics through whole exome and genome sequencing; it offers AI-based platforms for next-generation sequencing analysis, interpretation, and clinical reporting, including the Centrellis health intelligence platform for biopharma insights, drug discovery acceleration, pre-clinical and clinical trial support, advanced sequencing services, and analytics; additional services encompass Sema4 Signal for precision oncology from prevention to remission, carrier screening, noninvasive prenatal testing, newborn screening, hereditary cancer testing, and data services leveraging multidimensional genomic and clinical data. Founded in 2017 and headquartered in Stamford, Connecticut, the company serves healthcare providers, patients, health systems, and biopharma clients across the United States with operations including locations in New York and Maryland. In recent major changes, Sema4 acquired GeneDx from OPKO Health in 2022 for approximately $623 million in a combination of cash, stock, and milestones, strengthening its genomic capabilities; the company underwent a name change to GeneDx Holdings Corp. and shifted its ticker to WGS in January 2023 amid a strategic pivot to pediatric and rare disease testing, exiting reproductive health; it implemented restructuring with layoffs of about 700 employees, lab closures in Connecticut, and a focus on profitability by 2025, recently reporting strong Q2 2025 revenue growth of 69% in exome and genome testing.
Sema4.ai Launches Full Stack AI Agent Platform to Power Future of Enterprise Work
Sema4.ai Recognized in Multiple Gartner® Reports: Hype Cycle™ for the Future of Enterprise Applications and AI in Software Engineering
Sema4.ai Secures $30.5 Million to Bring AI to Enterprise Work
Sema4: Restructuring Plan Figures Don't Add Up
Sema4 Holdings Corporation (SMFR) Q3 2022 Earnings Call Transcript
Why Sema4 Holdings Stock Is Crashing Today
Sema4 Holdings Corp (SMFR) CEO Katherine Stueland on Q2 2022 Results - Earnings Call Transcript
Sema4 Holdings, Big Data For Precision Medicine Solutions
Sema4 Holdings Corp. (SMFR) Moves to Buy: Rationale Behind the Upgrade
Sema4 Holdings Corp. (SMFR) CEO Katherine Stueland on Q1 2022 Results - Earnings Call Transcript
Sema4 Holdings Corp. (SMFR) CEO Eric Schadt on Q4 2021 Results - Earnings Call Transcript
Sema4 Strengthens AI-Driven Genomic, Clinical Data Platform With $623M GeneDx Acquisition
Sema4 Stock (SMFR): Why The Price Jumped
Sema4 Holdings Corp. (SMFR) CEO Eric Schadt on Q3 2021 Results - Earnings Call Transcript
Why Sema4 Holdings Stock Is Sinking Today